Amit Munshi Amit Munshi, Arcutis Biotherapeutics WESTLAKE VILLAGE, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Amit Munshi has been appointed to the Arcutis Board of Directors effective December 4, 2025, and announced the retirement of founder and long-serving Board member Bhaskar Chaudhuri, PhD. Dr. Chaudhuri will continue as ...

Core Insights - Arcutis Biotherapeutics launched the "Free to Be Me" awareness campaign to highlight the emotional and physical challenges faced by approximately 36 million Americans with inflammatory skin diseases, including atopic dermatitis and seborrheic dermatitis [1][2][14] - The campaign features actress Tori Spelling and her daughter, who share their personal experiences managing skin conditions with the FDA-approved treatment ZORYVE® (roflumilast) [2][3][4] Company Overview - Arcutis Biotherapeutics is a commercial-stage biopharmaceutical company focused on innovations in immuno-dermatology, with a commitment to addressing the needs of individuals with immune-mediated dermatological diseases [21] - ZORYVE is the number one prescribed branded topical therapy for atopic dermatitis, seborrheic dermatitis, and plaque psoriasis, backed by robust clinical evidence from eight pivotal trials involving approximately 4,200 participants [12][10] Product Information - ZORYVE cream 0.15% is indicated for treating atopic dermatitis in adults and children aged 6 and older, showing a 31% rate of achieving clear or almost clear skin at 4 weeks in clinical trials [6][10] - ZORYVE foam 0.3% is indicated for seborrheic dermatitis in adults and children aged 9 and older, with 77% of users achieving clear or almost clear skin after 8 weeks of treatment [7][10] Clinical Evidence - Clinical trials demonstrated that ZORYVE cream and foam are safe and well-tolerated, with common side effects including headache, nausea, and application site pain [10][18] - The American Academy of Dermatology issued a strong recommendation for ZORYVE cream 0.15% for adult patients with mild to moderate atopic dermatitis, reflecting its clinical significance [13] Campaign Objectives - The "Free to Be Me" campaign aims to empower individuals with inflammatory skin conditions to engage in open conversations with healthcare providers about effective treatment options [14][8] - Tori Spelling's involvement in the campaign seeks to break the stigma surrounding skin conditions and encourage others to take control of their skin health [8][3]

Core Viewpoint - Arcutis Biotherapeutics, Inc. will report its third quarter 2025 financial results on October 28, 2025, and will host a virtual Investor Day to discuss these results and other strategic initiatives [1][2]. Company Overview - Arcutis Biotherapeutics is a commercial-stage medical dermatology company focused on innovative solutions for immune-mediated dermatological diseases, with a portfolio of advanced targeted topicals approved for three major inflammatory skin diseases [3]. - The company utilizes a unique dermatology development platform and expertise to create differentiated therapies targeting biologically validated conditions, resulting in a robust pipeline for various inflammatory dermatological issues [3]. Upcoming Events - The Investor Day will include presentations from the management team and a fireside chat with Douglas DiRuggiero, PA-C, DMSc, highlighting the company's strategy and clinical advancements [1][5]. - A Q&A session will follow the formal presentations, and a live webcast will be available on the company's website, with an archived replay posted afterward [2]. Strategic Focus - The event will provide an in-depth look into the company's long-term growth strategy for ZORYVE® (roflumilast), clinical development activities for new indications, and an overview of the capital allocation strategy and financial outlook [5].

Core Insights - Arcutis Biotherapeutics, Inc. announced that ZORYVE® (roflumilast) cream 0.15% received a strong recommendation from the American Academy of Dermatology (AAD) for managing adult atopic dermatitis (AD) [1][2] - The recommendation emphasizes ZORYVE's efficacy in improving pruritus and disease severity, along with its favorable tolerability and low treatment discontinuation rates [1][2] - ZORYVE is recognized as an effective, non-steroid option for daily management of mild to moderate AD in adults and pediatric patients aged 6 years and older [1][2] Company Overview - Arcutis Biotherapeutics is a commercial-stage biopharmaceutical company focused on innovations in immuno-dermatology [1][14] - The company has developed a portfolio of advanced targeted topicals approved for treating major inflammatory skin diseases, including AD, seborrheic dermatitis, and plaque psoriasis [5][14] - ZORYVE is the first FDA-approved branded topical phosphodiesterase-4 (PDE4) inhibitor indicated for these conditions [7][10] Product Information - ZORYVE cream 0.15% is specifically indicated for the topical treatment of mild to moderate AD in patients aged 6 years and older [10] - The product is part of a broader line that includes ZORYVE cream 0.3% and ZORYVE foam 0.3%, which are approved for plaque psoriasis and seborrheic dermatitis [6][9] - ZORYVE has been recognized for its effectiveness, receiving awards such as Glamour's Beauty and Wellness Award for "Eczema Product" in 2024 [6] Market Context - Atopic dermatitis affects approximately 16.5 million adults in the United States, highlighting a significant market opportunity for effective treatments [4][7] - The AAD's focused guideline update incorporates newly FDA-approved therapies, ensuring that healthcare professionals have access to the latest evidence-based recommendations for managing chronic conditions like AD [2][7]